Tag: heart failure

1. Pre-term birth was associated with significantly increased risk of adult-onset heart failure, particularly among those 18 to 43 years of age. Evidence Rating Level: 2 (Good) Preterm birth is a known risk factor for early-life heart failure (HF). However, less is known about its association with adult-onset HF. This Swedish...

1. Across all age groups at the time of diagnosis, younger gestational ages were associated with an increased risk of developing heart failure later in life. Evidence Rating Level: 2 (Good) Study Rundown: Preterm birth is an extremely common condition affecting mothers worldwide. The association between preterm birth and various cardiac...

1. In both obese and non-obese patients, NT-proBNP level <1000pg/mL during treatment showed favourable prognostic implications in heart failure with reduced ejection fraction. Evidence Rating Level: 2 (Good) While obesity itself is a major risk factor for developing heart failure, overweight and obese patients have been reported to have paradoxically better...

1. Risk factors, such as hypertension, diabetes, smoking and history of myocardial infarction, were associated with a higher risk of developing heart failure in younger populations compared to older populations. 2. Population-attributable risk of heart failure was better explained by traditional risk factors in younger than in elderly patients. Evidence Rating...

1. Patients who received omecamtiv mecarbil had slightly fewer systolic heart failure exacerbations compared to those who received placebo. 2. Serious adverse events occurred equally frequently in both groups. Evidence Rating Level: 1 (Excellent) Study Rundown: At present, no medications that directly stimulate systolic function have been shown to improve health outcomes...

1. Treatment with IV ferric carboxymaltose reduced the risk of heart failure hospitalizations in patients with iron deficiency and acute heart failure with a left ventricular ejection fraction less than 50%. 2. IV ferric carboxymaltose was generally safe but had no significant effect on the risk of cardiovascular death compared...

1. Sotagliflozin was shown to lower the risk of total number of deaths from cardiovascular causes and hospitalizations and urgent visits for heart failure in patients with diabetes and recent worsening heart failure compared to placebo. 2. Sotagliflozin was shown to be similar in the percentage of patients with adverse...

1. Sotagliflozin was shown to lower the risk of total number of deaths from cardiovascular causes and hospitalizations and urgent visits for heart failure in patients with diabetes and recent worsening heart failure compared to placebo. 2. Sotagliflozin was shown to be similar in the percentage of patients with adverse...

1. Receiving medications from a greater number of drug classes is linked to lower incidence of rehospitalization and death, for patients in heart failure with reduced ejection fraction (HFrEF). 2. Approximately half of HFrEF patients are not receiving medical therapies that follow clinical guidelines established by the American College of...